Innate Pharma has finally called time on a NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Innate Pharma has finally called time on a NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.